Wednesday, March 18, 2009

Teva Announces Approval and Launch of Generic Solodyn Extended-Release Tablets

Mar 18, 2009 - Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Medicis Pharmaceutical Corporation's acne treatment Solodyn® (Minocycline HCl) Extended-Release Tablets, 45 mg, 90 mg and 135 mg. Shipment of this product has commenced.

The details can be read here.

No comments: